DocStoX is a free AI-powered research platform for Indian equity markets, covering 6,800+ NSE & BSE stocks with prices, fundamentals, 326 financial ratios, shareholding, FII/DII flows, F&O, IPOs, a visual screener and AI stock scoring.

Yes. DocStoX has a free tier covering stock research, the screener, FII/DII data and educational guides, plus a free MCP API tier (50 tool calls/day) for AI assistants. A Pro plan adds higher limits and advanced features.

What data does DocStoX cover?

Every NSE & BSE listed stock (6,800+ instruments): EOD and intraday prices, income statement / balance sheet / cash flow, 326 ratios, quarterly shareholding, promoter pledge, mutual-fund holdings, FII/DII flows, F&O and option-chain data, analyst forecasts, IPOs, corporate actions and news.

Can AI assistants like ChatGPT or Claude use DocStoX data?

Yes. DocStoX runs a public Model Context Protocol (MCP) server at https://mcp.docstox.com/mcp with 39 tools, so Claude, ChatGPT, Cursor and other MCP clients can pull Indian market data directly. Setup and a free key are at https://docstox.com/mcp.

Positive impactIPO

Molbio Diagnostics IPO GMP Today: Grey Market Premium Signals 16% Listing Gain Ahead Of IPO Opening

NDTV Profit 2 hrs ago·10 Aug 2026, 3:00 am

Molbio Diagnostics is set to open its initial public offering (IPO) on August 10. The grey market premium (GMP) of Rs 122 indicates that the company's shares are trading at a premium in the unlisted market. This premium is a key indicator of investor sentiment and often suggests how the stock might perform on its listing day.

For investors, this GMP implies a potential listing gain of around 16%. This is a significant indicator of strong demand for the IPO. However, the actual listing price will be determined by the market on the day of the IPO allotment and listing. Investors should keep an eye on the final issue price and the market conditions on the listing day.

Moving forward, investors should watch the company's financial performance and the overall market sentiment. The company's ability to sustain its growth trajectory and the demand for its products will be crucial factors. The listing gain is just the beginning, and the stock's long-term performance will depend on the company's business fundamentals.

Affected stocks

Bullish1 stock

128

Molbio Diagnostics

1286089 Bullish

—

Bull / bear label is derived from the article's AI sentiment — indicative, not advice. Prices may be delayed.

Key takeaways

Concerns Molbio Diagnostics (1286089).
Category: IPO.
AI reads the tone as positive (potentially bullish) for the stock.
Assessed as a significant, market-relevant update.

Why it matters

A meaningful update for Molbio Diagnostics worth tracking. The tone is positive — historically associated with upward pressure, though not predictive. Use the price and stock snapshot to gauge how the market is responding.

Summary & analysis by DocStoX. Full story at NDTV Profit.